Literature DB >> 20028451

Pathogenic cysteine mutations affect progranulin function and production of mature granulins.

Jun Wang1, Philip Van Damme, Carlos Cruchaga, Michael A Gitcho, Jose Manuel Vidal, Manuel Seijo-Martínez, Lei Wang, Jane Y Wu, Wim Robberecht, Alison Goate.   

Abstract

Frontotemporal dementia with ubiquitin-positive inclusions (FTLD-U) can be caused by mutations in the progranulin gene (GRN). Progranulin (PGRN) is a cysteine-rich growth factor, which is proteolytically cleaved by elastase to produce several granulins (GRNs). All FTLD-U mutations in GRN characterized to date result in reduced secreted PGRN protein. We recently reported a Spanish family with progressive non-fluent aphasia and dementia in which a novel C521Y mutation segregates with disease. A second cysteine mutation (C139R) has also been reported to be disease specific. Allele-specific mRNA expression assays in brain reveal that the C521Y mutant allele is expressed at similar levels to the wild-type allele. Furthermore, plasma PGRN levels in C521Y carriers are comparable with non-carrier family relatives, suggesting that the mutation does not affect PGRN protein expression and secretion in vivo. Despite normal PGRN levels C521Y and C139R mutant GRNs show reduced neurite growth-stimulating activity in vitro. Further study revealed that these mutations also cause impaired cleavage of PGRN by elastase. Our data suggest that these mutations affect the function of full-length PGRN as well as elastase cleavage of PGRN into GRNs, leading to neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028451      PMCID: PMC2819556          DOI: 10.1111/j.1471-4159.2009.06546.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

Review 1.  Update on the neuropathological diagnosis of frontotemporal dementias.

Authors:  J Q Trojanowski; D Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2001-12       Impact factor: 3.685

2.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.

Authors:  G M McKhann; M S Albert; M Grossman; B Miller; D Dickson; J Q Trojanowski
Journal:  Arch Neurol       Date:  2001-11

3.  Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion.

Authors:  Sunita S Shankaran; Anja Capell; Alexander T Hruscha; Katrin Fellerer; Manuela Neumann; Bettina Schmid; Christian Haass
Journal:  J Biol Chem       Date:  2007-11-05       Impact factor: 5.157

4.  Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease.

Authors:  N Brouwers; K Sleegers; S Engelborghs; S Maurer-Stroh; I Gijselinck; J van der Zee; B A Pickut; M Van den Broeck; M Mattheijssens; K Peeters; J Schymkowitz; F Rousseau; J-J Martin; M Cruts; P P De Deyn; C Van Broeckhoven
Journal:  Neurology       Date:  2008-06-18       Impact factor: 9.910

Review 5.  Progranulin: normal function and role in neurodegeneration.

Authors:  Jason L Eriksen; Ian R A Mackenzie
Journal:  J Neurochem       Date:  2007-10-22       Impact factor: 5.372

6.  Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration.

Authors:  R Ghidoni; L Benussi; M Glionna; M Franzoni; G Binetti
Journal:  Neurology       Date:  2008-09-03       Impact factor: 9.910

7.  Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia.

Authors:  Livia Bernardi; Carmine Tomaino; Maria Anfossi; Maura Gallo; Silvana Geracitano; Angela Costanzo; Rosanna Colao; Gianfranco Puccio; Francesca Frangipane; Sabrina A M Curcio; Maria Mirabelli; Nicoletta Smirne; David Iapaolo; Raffaele Giovanni Maletta; Amalia C Bruni
Journal:  Neurobiol Aging       Date:  2008-03-07       Impact factor: 4.673

8.  Cortical atrophy and language network reorganization associated with a novel progranulin mutation.

Authors:  Carlos Cruchaga; Maria A Fernández-Seara; Manuel Seijo-Martínez; Lluis Samaranch; Elena Lorenzo; Anthony Hinrichs; Jaione Irigoyen; Cristina Maestro; Elena Prieto; Josep M Martí-Climent; Javier Arbizu; Maria A Pastor; Pau Pastor
Journal:  Cereb Cortex       Date:  2008-11-19       Impact factor: 5.357

9.  Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members.

Authors:  NiCole Finch; Matt Baker; Richard Crook; Katie Swanson; Karen Kuntz; Rebecca Surtees; Gina Bisceglio; Anne Rovelet-Lecrux; Bradley Boeve; Ronald C Petersen; Dennis W Dickson; Steven G Younkin; Vincent Deramecourt; Julia Crook; Neill R Graff-Radford; Rosa Rademakers
Journal:  Brain       Date:  2009-01-21       Impact factor: 13.501

10.  Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival.

Authors:  Philip Van Damme; Annelies Van Hoecke; Diether Lambrechts; Peter Vanacker; Elke Bogaert; John van Swieten; Peter Carmeliet; Ludo Van Den Bosch; Wim Robberecht
Journal:  J Cell Biol       Date:  2008-03-31       Impact factor: 10.539

View more
  31 in total

Review 1.  Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment.

Authors:  Hyeon-Sook Suh; Benjamin B Gelman; Sunhee C Lee
Journal:  J Neuroimmune Pharmacol       Date:  2014-03       Impact factor: 4.147

Review 2.  Human genetics as a tool to identify progranulin regulators.

Authors:  Alexandra M Nicholson; NiCole A Finch; Rosa Rademakers
Journal:  J Mol Neurosci       Date:  2011-05-28       Impact factor: 3.444

3.  Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling.

Authors:  Jindong Xu; Maria Xilouri; Julien Bruban; Junichi Shioi; Zhiping Shao; Ioannis Papazoglou; Kostas Vekrellis; Nikolaos K Robakis
Journal:  Neurobiol Aging       Date:  2011-08-04       Impact factor: 4.673

Review 4.  Cellular effects of progranulin in health and disease.

Authors:  Louis De Muynck; Philip Van Damme
Journal:  J Mol Neurosci       Date:  2011-05-25       Impact factor: 3.444

5.  Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice.

Authors:  Andrew E Arrant; Anthony J Filiano; Aashka R Patel; Madelyn Q Hoffmann; Nicholas R Boyle; Shreya N Kashyap; Vincent C Onyilo; Allen H Young; Erik D Roberson
Journal:  Neurobiol Dis       Date:  2018-11-15       Impact factor: 5.996

6.  Circulating progranulin as a biomarker for neurodegenerative diseases.

Authors:  Roberta Ghidoni; Anna Paterlini; Luisa Benussi
Journal:  Am J Neurodegener Dis       Date:  2012-08-02

Review 7.  Progranulin, lysosomal regulation and neurodegenerative disease.

Authors:  Aimee W Kao; Andrew McKay; Param Priya Singh; Anne Brunet; Eric J Huang
Journal:  Nat Rev Neurosci       Date:  2017-04-24       Impact factor: 34.870

8.  Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features.

Authors:  Celeste M Karch; Lubov Ezerskiy; Veronica Redaelli; Anna Rita Giovagnoli; Pietro Tiraboschi; Giuseppe Pelliccioni; Paolo Pelliccioni; Dimos Kapetis; Ilaria D'Amato; Elena Piccoli; Maria Giulia Ferretti; Fabrizio Tagliavini; Giacomina Rossi
Journal:  Neurobiol Aging       Date:  2015-11-02       Impact factor: 4.673

9.  Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis.

Authors:  Andrew E Arrant; Vincent C Onyilo; Daniel E Unger; Erik D Roberson
Journal:  J Neurosci       Date:  2018-01-29       Impact factor: 6.167

Review 10.  Mouse models of frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Ann Neurol       Date:  2012-12       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.